🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
335

Quick answer

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Recombinant human arylsulfatase A

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  2. Recombinant human heparan N-sulfatase (rhHNS)

    Takeda

    Mucopolysaccharidosis (MPS)

    phase 2 mab completed

    1 trial

  3. Recombinant human heparan N-sulfatase [rhHNS]

    Takeda

    Sanfilippo Syndrome

    phase 2 small molecule completed

    1 trial

  4. Recombinant human hyaluronidase + immune globulin intravenous

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 mab completed

    1 trial

  5. Relugolix

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  6. Replagal (agalsidase alfa)

    Takeda

    Fabry Disease

    phase 2 mab completed

    1 trial

  7. Roflumilast

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  8. Romidepsin

    Takeda

    Lymphoma, T-Cell, Peripheral

    phase 2 small molecule terminated

    1 trial

  9. SHP611

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

  10. SHP648

    Takeda

    Hemophilia B

    phase 2 gene therapy terminated

    1 trial

  11. SHP655

    Takeda

    Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

    phase 2 small molecule completed

    1 trial

  12. SM101

    Takeda

    Immunoglobulin A Nephropathy

    phase 2 mab terminated

    1 trial

  13. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  14. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  15. SPD489 20 mg

    Takeda

    Sleep Deprivation

    phase 2 small molecule completed

    1 trial

  16. SPD503 (Guanfacine HCl)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  17. SPD503 (extended-release Guanfacine hydrochloride)

    Takeda

    Generalized Anxiety Disorder (GAD)

    phase 2 small molecule completed

    1 trial

  18. SPD557

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule terminated

    1 trial

  19. SPD602

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule terminated

    2 trials

  20. SPD602

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  21. SPD602 (FBS0701, SSP-004184)

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule completed

    1 trial

  22. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  23. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  24. SSP-002358 (0.1 mg) + PPI

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  25. SSP-004184AQ

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  26. SYR-619

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  27. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  28. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  29. Soticlestat

    Takeda

    Complex Regional Pain Syndrome

    phase 2 small molecule completed

    1 trial

  30. Soticlestat

    Takeda

    15q Duplication Syndrome

    phase 2 small molecule completed

    1 trial

  31. Stem cells

    Takeda

    Rheumatoid Arthritis Aggravated

    phase 2 gene therapy completed

    1 trial

  32. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  33. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  34. TAK-018

    Takeda

    Crohn Disease

    phase 2 small molecule terminated

    1 trial

  35. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  36. TAK-062

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  37. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  38. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  39. TAK-079

    Takeda

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

  40. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  41. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  42. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  43. TAK-226

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  44. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  45. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  46. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  47. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  48. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.